The AABB website is currently experiencing technical issues related to login and SSO. Thank you for your patience as we work to get this resolved. If you need immediate assistance, please contact us.
AABB is the voice of the blood and cellular therapies community before the Food and Drug Administration and FDA advisory committees, such as the Blood Products Advisory Committee and Cellular, Tissue, and Gene Therapies Advisory Committee. The Association engages stakeholders within AABB's membership and the broader community to develop materials that provide FDA with the community’s position on draft guidances, proposed regulations and policies, and research priorities. These AABB-led efforts create an important dialogue with federal regulators that helps promote a strong and safe supply of blood and cells.
July 16, 2025
‘Ask the FDA and CMS/CLIA’ Questions Due Aug. 8
July 16, 2025
July 09, 2025
AABB is now the Association for the Advancement of Blood & Biotherapies. Learn more about our new name and brand – and watch as we evolve throughout 2022.
4550 Montgomery Avenue
Suite 700, North Tower
Bethesda, MD 20814
301.907.6977
AABB (Association for the Advancement of Blood & Biotherapies) is an international, not-for-profit organization representing individuals and institutions involved in the fields of transfusion medicine and biotherapies. The Association works collaboratively to advance the field through the development and delivery of standards, accreditation and education programs. AABB is dedicated to its mission of improving lives by making transfusion medicine and biotherapies safe, available and effective worldwide.
©2022 All Rights Reserved. AABB - Association for the Advancement of Blood & Biotherapies
Web Design and Development by Matrix Group International, Inc.